NEW YORK, Aug. 11 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB), ("the Company" or "AOBO"), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products in China, announced today that the Audit Committee of the Board of Directors of AOBO approved the engagement of Ernst & Young Hua Ming ("EY") as the Company's independent registered public accounting firm for the year ending December 31, 2009.
During the years ended December 31, 2007 and 2008 and through August 10, 2009, there were no disagreements with the Company's prior independent auditor, Weinberg & Company, P.A., on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Weinberg, would have caused Weinberg to make reference to the subject matter of the disagreements in its reports on the consolidated financial statements for such years.
About American Oriental Bioengineering, Inc.
American Oriental Bioengineering, Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products in China.
|SOURCE American Oriental Bioengineering, Inc.|
Copyright©2009 PR Newswire.
All rights reserved